← Back
Retension Pharmaceuticals
RTSN · listed on Nasdaq · worth $109.06 million
$13.09
−3.18% today
Two insider buys in the last year, $369.6K in all. None in the last two weeks.
Different buyers at onceDirector Franklin M. Berger bought, and 3 big investors reported new stakes, within 3 days · Oct 16
Green dot = an insider boughtA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
538.7K shares
6% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders bought Retension Pharmaceuticals stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
CHIEF EXECUTIVE OFFICER
Eric L. Keller
Bought $249.6K on Oct 13 — 20,800 shares at $12.00, 4.9% of what they now own.
No earlier purchases to measure
Director
Franklin M. Berger
Bought $120K on Oct 13 — 10,000 shares at $12.00, held through a trust or family, 100% of what they now own.
No earlier purchases to measure
Big investors
People and funds that reported owning 5% or more of Retension Pharmaceuticals, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.PVG Asset Management8.3%Oct 16
Filed by someone who owns 5% or more and does not plan to influence the company.Lytton Laurence W7.4%Oct 15
Filed by someone who owns 5% or more and may try to influence how the company is run.Keller Eric L.7.1%Oct 14
All reports
Every insider trade and SEC report we hold for Retension Pharmaceuticals.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue